American College of Rheumatology

Certa Therapeutics presents positive data from a Phase 2 clinical study highlighting the potential benefit of FT011 as a novel treatment for scleroderma

Retrieved on: 
Wednesday, November 15, 2023
Safety, Therapy, Treatment, University, Aes, Scleroderma, Clutch (eggs), Disease, Clinical trial, Biotechnology, EMA, Patient, Royal Free Hospital, FDA, American College of Rheumatology, American College, University College London, RSS, Transcriptomics technologies, MD, Quality of life, ACR, Inflammation, Fibrosis, Pharmaceutical industry, Atlit, Rheumatology

The study safety profile demonstrated that FT011 was safe and well tolerated, with no differences in adverse event (AE) rates between the treatment arms.

Key Points: 
  • The study safety profile demonstrated that FT011 was safe and well tolerated, with no differences in adverse event (AE) rates between the treatment arms.
  • There were no serious AEs reported in the study, nor any AEs resulting in study drug interruption, withdrawal or discontinuation.
  • This suggests that FT011 may have a positive effect for scleroderma patients by reducing the inflammation and fibrosis associated with the disease.
  • It is important to advance safe and effective treatments through clinical development, given the limited therapeutic options for scleroderma patients.

Biosplice Presents Successful Structure and Pain Results from Completed Phase 3 Long-Term Extension Clinical Trial for Lorecivivint for the Treatment of Knee Osteoarthritis

Retrieved on: 
Monday, November 13, 2023
Observation, Safety, SAN, Therapy, Osteoarthritis, CLK, Publication, Patient, American College, American College of Rheumatology, Cartilage, Biosplice Therapeutics, MD, Knee, Pain, KL2, Physician, Injection, Pharmaceutical industry, Vaccine, OA

Results from the study support the potential for multiple injections of lorecivivint to delay structural progression and provide symptomatic benefit.

Key Points: 
  • Results from the study support the potential for multiple injections of lorecivivint to delay structural progression and provide symptomatic benefit.
  • We are excited to continue to investigate lorecivivint as a treatment option for knee OA.”
    OA-07 was a long-term extension trial, which enrolled patients who completed OA-11, a prior 12-month Phase 3 study.
  • The primary efficacy objective of OA-07 was to measure the structure improvement potential of lorecivivint over multiple years and multiple injections.
  • A copy of the presentation materials can be seen on the Publications page of the Biosplice Therapeutics website.

aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023

Retrieved on: 
Monday, November 13, 2023
NRP2, SAN, Neuropilin, Inflammation, Scar, Sarcoidosis, ILD, Scleroderma, Systemic scleroderma, Patient, Myelocyte, Rheumatoid arthritis, American College of Rheumatology, ATyr Pharma, American College, Small RNA, ACR, Poster, Fibrosis, Pharmaceutical industry

The poster will be available on the aTyr website once presented.

Key Points: 
  • The poster will be available on the aTyr website once presented.
  • The poster presents findings from preclinical models of rheumatoid arthritis (RA) and RA-associated ILD (RA-ILD), where NRP2, efzofitimod’s binding partner, is known to be expressed on pro-inflammatory synovial macrophages.
  • An animal knockout model for NRP2 demonstrated that NRP2 deficiency exacerbated disease pathology in preclinical models of inflammatory disease.
  • These forms of ILD have limited therapeutic options and there is a need for safer and more effective, disease-modifying treatments that improve outcomes.

aTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate Update

Retrieved on: 
Thursday, November 9, 2023
NRP2, Research, Safety, SAN, Neuropilin, PST, D, BLA, Sarcoidosis, ILD, Scleroderma, International, Investment, Systemic scleroderma, ERS, Clinical trial, Patient, European Respiratory Society, DSMB, Rheumatoid arthritis, ATyr Pharma, American College, American College of Rheumatology, Small RNA, The Journal, Frontiers, Skin, ACR, Poster, Biologics license application, Pharmaceutical industry, Pharmacology, Kyorin

SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced third quarter 2023 results and provided a corporate update.

Key Points: 
  • Ended the third quarter of 2023 with $105.6 million in cash, cash equivalents and investments.
  • SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced third quarter 2023 results and provided a corporate update.
  • Based on current enrollment projections, the Company expects to complete enrollment in the study early in the second quarter of 2024.
  • G&A Expenses: General and administrative expenses were $2.6 million for the third quarter of 2023.

ROME Therapeutics Presents First Data to Validate LINE-1 RT as a Novel Target in Autoimmune Diseases and the Therapeutic Potential of its First-in-Class LINE-1 RT Inhibitors

Retrieved on: 
Thursday, November 16, 2023
Health, Biotechnology, DNA, Therapy, Pathology, University, Cytoplasm, Keratinocyte, Patient, UV, Autoantibody, American College of Rheumatology, Autoimmune disease, Heart, Kidney, American College, SLE, DSM-IV codes, Drug discovery, RT, RNA, AGS, Skin, ACR, Quality of life, Lupus, Poster, Biology, Inflammation, Pharmaceutical industry, Vaccine, Rheumatology

Data also demonstrated the therapeutic potential of the company’s first-in-class LINE-1 RT inhibitors to stop disease-driving inflammation.

Key Points: 
  • Data also demonstrated the therapeutic potential of the company’s first-in-class LINE-1 RT inhibitors to stop disease-driving inflammation.
  • Additionally, the poster highlighted the first preclinical data demonstrating the therapeutic potential of ROME’s first-in-class inhibitors of LINE-1 RT.
  • These data are the first to validate LINE-1 RT as a novel target for potential therapeutic intervention across a wide range of autoimmune diseases,” said Rosana Kapeller, M.D., Ph.D., President, CEO and Co-founder of ROME.
  • “We’re also pleased to share the first in vivo and in vitro data validating the therapeutic effect of our first-in-class LINE-1 RT inhibitors in the autoimmune disease setting.

Swing Therapeutics Announces Positive Results from Pivotal Phase 3 Trial of Stanza, a Digital Therapy for Fibromyalgia Symptoms

Retrieved on: 
Tuesday, November 14, 2023
Biotechnology, Technology, FDA, Health, General Health, Pharmaceutical, Health Technology, Medical Devices, Apps, Applications, Software, Clinical Trials, ACT, RCT, Fatigue, Fibromyalgia, Depression, De novo, Pivotal, Randomized controlled trial, Food, Commitment, Therapy, University of Michigan, CBT, Cognitive behavioral therapy, Patient, PROMIS, American College of Rheumatology, PGIC, American College, BDI, MD, Sleep, Phase 3, University, University of Cincinnati, FIQ, Doctor of Philosophy, Guideline, ACR, Chronic pain, PIPS, Pharmaceutical industry, Medical imaging, Medical device, Stanza, Swing

Swing Therapeutics, a leading developer of digital therapies for chronic pain conditions, today announced the successful completion of and positive results from its pivotal Phase 3 PROSPER-FM trial on Stanza, a self-guided smartphone-based behavioral therapy for the treatment of fibromyalgia symptoms in adult patients.

Key Points: 
  • Swing Therapeutics, a leading developer of digital therapies for chronic pain conditions, today announced the successful completion of and positive results from its pivotal Phase 3 PROSPER-FM trial on Stanza, a self-guided smartphone-based behavioral therapy for the treatment of fibromyalgia symptoms in adult patients.
  • Results from this multi-center, randomized controlled trial (RCT) were presented at the American College of Rheumatology (ACR) 2023 annual meeting this week.
  • Swing received De Novo marketing authorization from the U.S. Food and Drug Administration (FDA) for Stanza in May 2023, making it the first prescription digital therapeutic indicated for treating fibromyalgia symptoms.
  • It delivers acceptance and commitment therapy (ACT), a type of cognitive behavioral therapy (CBT) with proven efficacy in treating fibromyalgia and other chronic pain conditions.

Northwell Health Pediatric Rheumatologist Recognized for Lifetime Achievement by the American College of Rheumatology

Retrieved on: 
Tuesday, November 14, 2023
Children, Biotechnology, Other Consumer, Other Health, Health, General Health, Other Science, Research, Consumer, Science, Teens, Interest group, CCMC, Hope, Pediatrics, Patient, Multimedia, Lupus, American College of Rheumatology, Arthritis, American College, Northwell Health, Rheumatology, Medical research, Dermatomyositis, Mentorship, Credit, MBA, MD, Eberhard, ACR, ARP, Vasculitis, Nursing, Child

For her dedication to research and leadership in rheumatology, Northwell Health’s Cohen Children’s Medical Center (CCMC) pediatric rheumatologist and Feinstein Institutes for Medical Research scientist Barbara Anne Eberhard, MD , has been awarded top honors by the American College of Rheumatology (ACR) and the Association of Rheumatology Professionals (ARP).

Key Points: 
  • For her dedication to research and leadership in rheumatology, Northwell Health’s Cohen Children’s Medical Center (CCMC) pediatric rheumatologist and Feinstein Institutes for Medical Research scientist Barbara Anne Eberhard, MD , has been awarded top honors by the American College of Rheumatology (ACR) and the Association of Rheumatology Professionals (ARP).
  • Dr. Eberhard was recognized, and named an “ACR Master,” during the ACR Convergence 2023 annual conference which is being held November 10-15 in San Diego, California.
  • View the full release here: https://www.businesswire.com/news/home/20231114668794/en/
    Dr. Barbara Anne Eberhard was recognized for lifetime achievement by the American College of Rheumatology.
  • (Credit: Feinstein Institutes)
    The ACR Master recognition is awarded to physician-researchers who have made significant contributions to the field of rheumatology.

Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology

Retrieved on: 
Monday, November 13, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, EOS, Serum albumin, ALC, European Renal Association, MMF, Itolizumab, Safety, Ono Pharmaceutical, Dialysis, Type, Children's Organ Transplant Association, Patient, Bruce Steel, American College of Rheumatology, Novel, American College, Therapy, Lupus nephritis, Standard of care, ORR, Infection, Partnership, EGFR, CD6, S1P, EULAR, AMP, ACR, Trial of the century, Proteinuria, Pharmaceutical industry, Silviculture, Nursing, UPCR, Medicine, Lupus

“It’s important that we saw both early and large reductions in proteinuria,” said Dr.

Key Points: 
  • “It’s important that we saw both early and large reductions in proteinuria,” said Dr.
  • Results are comparable to those observed in the Phase 3 AURORA1 study of voclosporin (ORR 70% at 6 and 12 months in active treatment).
  • Consistent with the decline in UPCR overtime, subjects were able to taper their systemic corticosteroids over the course of the study.
  • The poster presentation is available on the Presentations page of Equillium’s website under the Lupus tab.

Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, November 13, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Downregulation and upregulation, ISCB Senior Scientist Award, Annual general meeting, Safety, ALT, Cohort, UPCR, AIH, Immunosuppression, Clinical trial, Patient, KZR, OLE, Week, American College of Rheumatology, Immunotherapy, Mount Everest, G&A, Pharmacokinetics, Polymyositis, American College, PD-1, University, Dermatomyositis, Lupus nephritis, SITC, Total, Autoimmune hepatitis, Growth, CRR, Congress, ACR, APLAR, Society, Sec61, Pharmaceutical industry, Rheumatology, Kezar Pavilion

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the third quarter ended September 30, 2023 and provided a business update.

Key Points: 
  • Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the third quarter ended September 30, 2023 and provided a business update.
  • In addition, Kezar recently announced a strategic restructuring to prioritize long-term growth and focus resources on its clinical-stage programs.
  • Actions to prioritize clinical programs and implement cost saving measures are expected to extend Kezar’s cash runway into late 2026.
  • Research and development expenses for the third quarter of 2023 increased by $9.8 million to $23.7 million compared to $13.9 million in the third quarter of 2022.

Latest Updates of Viva's Portfolio Companies

Retrieved on: 
Monday, December 4, 2023
JAK1, NMPA, Patient, American College of Rheumatology, Bayer, SUA, Neoplasm, Cataract, Therapy, URAT1, MBA, Cancer, Health care, Inflammation, Fabry disease, Safety, Toxicity, IND, SHP2, USD, Strong, Letter, Woman, EA Phenomic, Pharmacokinetics, VBI, HER2, MPM, Antibody, GCS, GEJ, Boehringer, Research, Plasma, Boehringer Ingelheim, Clinical trial, Investment, MaRS Discovery District, FDA, American College, Phase II, Clostridial necrotizing enteritis, Selective, MPH, ACR, EGFR, Pharmaceutical industry, Astellas Pharma, Phase, Deka, Facet joint arthrosis

TORONTO & WALTHAM, Mass.--(BUSINESS WIRE)--On Nov. 29th, Phenomic AI ("Phenomic"), invested and incubated by Viva BioInnovator (VBI), announced that they have entered into a strategic collaboration and licensing agreement with Boehringer Ingelheim to discover targets important in stroma-rich cancers. The partners will leverage Phenomic's expertise in target identification and stromal biology based on its scTx® single-cell transcriptomics platform which will greatly enhance Boehringer's efforts to develop first-in-class medicines to transform the lives of people with cancer by delivering meaningful advances with the ultimate goal to cure a range of cancers. Phenomic will receive upfront and near-term payments of approximately $9 million including research funding and collaboration milestones. Phenomic is also eligible to receive more than USD $500 million in licensing fees as well as clinical, regulatory and commercial milestones in addition to royalties on future product sales.

Key Points: 
  • HONG KONG, Dec. 4, 2023 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development.
  • This continuous innovation keeps companies up to date and promotes the evolution of R&D and the success of commercialization.
  • Recently, Viva's portfolio companies have new updates.
  • Phenomic will receive upfront and near-term payments of approximately $9 million including research funding and collaboration milestones.